Zions Bancorporation National Association UT Purchases 3,657 Shares of Vericel Corporation $VCEL

Zions Bancorporation National Association UT grew its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 7.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,848 shares of the biotechnology company’s stock after purchasing an additional 3,657 shares during the period. Zions Bancorporation National Association UT’s holdings in Vericel were worth $2,334,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Ameritas Advisory Services LLC acquired a new position in Vericel during the 2nd quarter valued at approximately $30,000. CWM LLC raised its stake in shares of Vericel by 101.3% during the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 694 shares during the last quarter. AlphaQuest LLC purchased a new position in shares of Vericel during the 2nd quarter valued at about $60,000. Gagnon Securities LLC acquired a new position in Vericel in the first quarter valued at approximately $137,000. Finally, US Bancorp DE boosted its holdings in Vericel by 29.9% during the first quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company’s stock worth $137,000 after buying an additional 706 shares in the last quarter.

Vericel Trading Up 0.5%

Shares of NASDAQ VCEL opened at $38.94 on Monday. The stock has a market capitalization of $1.96 billion, a PE ratio of 324.53 and a beta of 1.41. Vericel Corporation has a twelve month low of $29.24 and a twelve month high of $63.00. The stock has a fifty day simple moving average of $33.78 and a 200-day simple moving average of $37.70.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. The company had revenue of $67.50 million for the quarter, compared to analyst estimates of $64.57 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm’s quarterly revenue was up 16.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.02) EPS. Vericel has set its FY 2025 guidance at EPS. On average, equities analysts predict that Vericel Corporation will post 0.14 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Canaccord Genuity Group reduced their price target on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a report on Friday, August 1st. BTIG Research cut Vericel from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 17th. Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday. Truist Financial lowered their target price on shares of Vericel from $46.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Finally, Wall Street Zen raised shares of Vericel from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vericel presently has a consensus rating of “Moderate Buy” and a consensus price target of $58.40.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.